Remifemin reacquisition
This article was originally published in The Tan Sheet
Executive Summary
Enzymatic Therapy acquires distribution rights for menopausal treatment product Remifemin from GlaxoSmithKline, according to a May 25 announcement. GSK will transfer rights for the product to the Green Bay, Wisc.-based firm when the transaction becomes effective June 20. Enzymatic Therapy says it will partner with German Remifemin manufacturer Shaper & Brummer to boost product distribution and market share. The firm distributed the hormone-free menopausal therapy between 1995 and 2000, prior to the product's entry to the mass market under GSK...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.